Phenotypic and Genetic Characterization of Circulating Tumor Cells by Combining Immunomagnetic Selection and FICTION Techniques

The presence of circulating tumor cells (CTCs) in breast cancer patients has been proven to have clinical relevance. Cytogenetic characterization of these cells could have crucial relevance for targeted cancer therapies. We developed a method that combines an immunomagnetic selection of CTCs from peripheral blood with the fluorescence immunophenotyping and interphase cytogenetics as a tool for investigation of neoplasm (FICTION) technique. Briefly, peripheral blood (10 ml) from healthy donors was spiked with a predetermined number of human breast cancer cells. Nucleated cells were separated by double density gradient centrifugation of blood samples. Tumor cells (TCs) were immunomagnetically isolated with an anti-cytokeratin antibody and placed onto slides for FICTION analysis. For immunophenotyping and genetic characterization of TCs, a mixture of primary monoclonal anti-pancytokeratin antibodies was used, followed by fluorescent secondary antibodies, and finally hybridized with a TOP2A/HER-2/CEP17 multicolor probe. Our results show that TCs can be efficiently isolated from peripheral blood and characterized by FICTION. Because genetic amplification of TOP2A and ErbB2 (HER-2) in breast cancer correlates with response to anthracyclines and herceptin therapies, respectively, this novel methodology could be useful for a better classification of patients according to the genetic alterations of CTCs and for the application of targeted therapies.

[1]  Torsten Haferlach,et al.  Which compartments are involved in Philadelphia‐chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May‐Grünwald‐Giemsa staining and fluorescence in situ hybridization techniques , 1997, British journal of haematology.

[2]  M. J. van de Vijver,et al.  Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy , 2006, British Journal of Cancer.

[3]  J. Mendelsohn,et al.  Circulating tumor cells in breast cancer: Advanced tools for “tailored” therapy? , 2006, Proceedings of the National Academy of Sciences.

[4]  C. Larsson,et al.  Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping , 2000, Genes, chromosomes & cancer.

[5]  W. Lam,et al.  Comprehensive copy number profiles of breast cancer cell model genomes , 2006, Breast Cancer Research.

[6]  D. Mavroudis,et al.  Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA–Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer , 2004, Clinical Cancer Research.

[7]  Y. Tagawa,et al.  Evaluation of Metastatic Potential of Gastric Tumors by Staining for Proliferating Cell Nuclear Antigen and Chromosome 17 Numerical Aberrations , 2001, Annals of Surgical Oncology.

[8]  M. Sales,et al.  Application of combined immunofluorescence and fluorescence in situ hybridization on paraffin‐embedded sections to characterize T‐cell lymphoma with EBV‐infected B‐cell blasts , 2004, Genes, chromosomes & cancer.

[9]  S. Knuutila,et al.  Cell lineage involvement in four patients with myelodysplastic syndrome and t(1;7) or trisomy 8 studied by simultaneous immunophenotyping and fluorescence in situ hybridization. , 1993, Cancer genetics and cytogenetics.

[10]  A. Toh-E,et al.  Identification of the genetic locus for the structural gene and a new regulatory gene for the synthesis of repressible alkaline phosphatase in Saccharomyces cerevisiae , 1982, Molecular and cellular biology.

[11]  B. Schlegelberger,et al.  Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  E. Liu,et al.  Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer. , 2006, Current cancer drug targets.

[13]  Å. Borg,et al.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. , 2000, The American journal of pathology.

[14]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[15]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[16]  G. Schlimok,et al.  Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization. , 1996, Cancer genetics and cytogenetics.

[17]  J. Fridlyand,et al.  Deletion of Chromosome 11 q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer , 2007 .

[18]  P. Dam,et al.  Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer? , 2005, Current opinion in oncology.

[19]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Speicher,et al.  Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[22]  W. Chan,et al.  Mantle Cell Lymphoma With Plasma Cell Differentiation , 2006, The American journal of surgical pathology.

[23]  R. Eils,et al.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. , 2005, Cancer cell.

[24]  O. Olopade,et al.  Molecular-Cytogenetic Analysis of HER-2 / neu Gene in BRCA 1-associated Breast Cancers 1 , 2002 .

[25]  S. Mariotti,et al.  Aneuploidy in oncocytic lesions of the thyroid gland: Diffuse accumulation of mitochondria within the cell is associated with trisomy 7 and progressive numerical chromosomal alterations , 2003, Genes, chromosomes & cancer.

[26]  M. Untch,et al.  The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[28]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[29]  R. Eils,et al.  From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Hsu,et al.  Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. , 1981, Cancer genetics and cytogenetics.

[31]  Michael D Feldman,et al.  Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. , 2002, Cancer research.

[32]  J. Fridlyand,et al.  Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. , 2007, Cancer research.

[33]  R. Siebert,et al.  Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines , 2000, Virchows Archiv.

[34]  E. Liu,et al.  Her-2/neu and Topoisomerase iiα in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[35]  K. Pantel,et al.  Recent translational research: circulating tumor cells in breast cancer patients , 2006, Breast Cancer Research.

[36]  H. Scherthan,et al.  Discrimination of distinct subpopulations within a tumor with combined double immunophenotyping and interphase cytogenetics. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Ingle,et al.  Evaluation of a Panel of Tumor Markers for Molecular Detection of Circulating Cancer Cells in Women with Suspected Breast Cancer , 2005, Clinical Cancer Research.

[39]  J. Fletcher,et al.  HER-2/neu (c-erb-B2) gene and protein in breast cancer. , 1999, American journal of clinical pathology.

[40]  M. Delgado-Rodríguez,et al.  Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis , 2003, International journal of cancer.

[41]  F. Waldman,et al.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.

[42]  Y. Chen,et al.  Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. , 2000, Cancer research.

[43]  S. Schwartz,et al.  Prostate cancer and other xenografts from cells in peripheral blood of patients. , 2000, Cancer research.

[44]  J. Isola,et al.  Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. , 2001, Cancer research.

[45]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[46]  Å. Borg,et al.  Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. , 1999, Genes, chromosomes & cancer.

[47]  R. Knuechel,et al.  Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin‐embedded breast cancer , 2005, The Journal of pathology.